The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes (GA-17b)

University of Copenhagen

Status: Enrolling

Conditions: Blood Flow

Treatments: Other: GIPR antagonist / study tool; Other: Saline / placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT06426823

GA-17b

Details and patient eligibility

About

This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with type 2 diabetes.

Full description

Each participant will attend four independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose/water): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2).

MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.

Enrollment: 10 estimated patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes
• BMI 20-35 kg/m^2
• Age 20-80

Exclusion criteria

• Not MRI-compatible implants
• Claustrophobia
• Abnormal kidney or liver function
• Anemia
• Planned weight loss or change in diet
• Hypertension
• Other conditions that could be expected to affect the primary or secondary outcomes

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

10 participants in 4 patient groups, including a placebo group

Saline and oral water (SAL-WAT)

Placebo Comparator group

Description:

Saline infusion, oral water ingestion

Treatment:

Other: Saline / placebo

Saline infusion and oral glucose ingestion (SAL-GLU)

Active Comparator group

Description:

Saline infusion, oral glucose ingestion

Treatment:

Other: Saline / placebo

GIP(3-30)NH2 infusion and oral water ingestion (GIA-WAT)

Experimental group

Description:

GIPR antagonist infusion, oral water ingestion

Treatment:

Other: GIPR antagonist / study tool

GIP(3-30)NH2 infusion and oral glucose ingestion (GIA-GLU)

Experimental group

Description:

GIPR antagonist infusion, oral glucose ingestion

Treatment:

Other: GIPR antagonist / study tool